Empagliflozin for chronic low blood sodium in certain fluid states
Treatments studied
Part of Brain & nervous system, Digestive system, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether empagliflozin, a blood-sugar–related medicine, can safely improve chronic low blood sodium when you are not too “dry” or have an imbalanced fluid state. It may help stabilize sodium levels and related health symptoms, but you must meet specific blood and organ-function criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic low sodium that is not due to too-high body “concentration” (non–high osmolar), with sodium below 135 mmol/L
- Your low sodium is described as “euvolemic” (normal body fluid) or “hypervolemic” (too much body fluid)
- You are not severely ill from low sodium and do not need urgent treatment with 3% salt (or intensive/intermediate care) now
- You are not known to be allergic to empagliflozin or related medicines
- Your kidney function is not severely reduced (eGFR must be 20 mL/min/1.73 m² or higher)
- Your liver and thyroid/adrenal conditions are controlled (or meet lab limits), and blood pressure is not too low
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Hear when a new Hyponatremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.